Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

I now have all the information needed from the textbooks. Let me compile the full detailed answers for both case studies.

Case Study 1 - Organophosphorus (OP) Insecticide Poisoning

Q1. How the Signs and Symptoms Are Produced

Organophosphorus compounds irreversibly inhibit acetylcholinesterase (AChE) by phosphorylating its esteratic site. This prevents the breakdown of acetylcholine (ACh) at synapses, causing ACh to accumulate and overstimulate cholinergic receptors everywhere. The resulting "cholinergic crisis" has three components:

Muscarinic effects (parasympathetic overstimulation - remember SLUDGE/DUMBELS):

Profuse sweating - overstimulation of muscarinic receptors on sweat glands (sympathetic cholinergic)
Increased salivation - excess glandular secretions
Difficulty breathing - bronchospasm + bronchorrhea (excess secretions)
Miosis (pin-point pupils) - sphincter pupillae contraction via M3 receptors; this is the most reliable sign of OP poisoning
Bradycardia (pulse 40/min) - ACh at cardiac M2 receptors slows the SA node
Rhonchi - bronchospasm and excess bronchial secretions cause wheezing/rhonchi

Nicotinic effects (at NMJ and autonomic ganglia):

Muscle weakness - initial fasciculations from NMJ overstimulation, followed by depolarizing blockade causing flaccid paralysis (similar to succinylcholine overdose)

CNS effects:

Anxiety, seizures, coma (from ACh accumulation in the CNS)

The "aging" phenomenon: if the OP compound permanently and irreversibly bonds to AChE (aging), new enzyme must be synthesized over weeks before recovery. - Tintinalli's Emergency Medicine, p.1345

Q2. General Measures for the Patient

Remove from exposure - Remove contaminated clothing, wash skin thoroughly with soap and water (decontamination); protect healthcare workers with gloves
Secure the airway - Intubation and mechanical ventilation if respiratory failure (atropine reduces secretions but does NOT reverse muscle weakness)
Supplemental oxygen
IV access - establish large-bore IV, send blood for RBC-AChE levels before giving pralidoxime
Cardiac monitoring - ECG monitoring for bradycardia and arrhythmias
Seizure management - benzodiazepines if seizures occur
Poison control center consultation - identify exact agent
Supportive care - fluids, glucose monitoring, urinary catheter

Q3. Two Drugs with Dose, Route, and Basis of Use

Drug 1: Atropine (Anticholinergic)

Dose: Initial 1.2-3.0 mg IV (adults); doubled every 5 minutes until secretions dry up, HR >80/min, BP >80 mmHg systolic. Massive doses (hundreds of mg) may be needed.
Route: IV preferred; 2-6 mg IM if no IV access
Basis: Atropine is a competitive muscarinic receptor antagonist. It blocks ACh at M1, M2, M3 receptors, reversing bronchospasm, bronchorrhea, bradycardia, and excessive secretions. It does NOT reverse nicotinic (muscle weakness) effects. Endpoint is drying of secretions, NOT pupil dilation.

Drug 2: Pralidoxime (PAM, 2-PAM - Oxime)

Dose: 30 mg/kg IV bolus, followed by IV infusion of 8 mg/kg/hour (WHO recommendation). Continue for 24-48 hours.
Route: IV
Basis: Pralidoxime is an oxime that regenerates (reactivates) AChE by displacing the organophosphate from the enzyme's active site. It reverses both muscarinic AND nicotinic effects (including muscle paralysis), unlike atropine which only treats muscarinic effects. It must be given before "aging" occurs, after which the bond becomes irreversible and pralidoxime is ineffective. - Tintinalli's Emergency Medicine, pp.1345-1346

Q4. Why Oximes Are NOT Effective in Carbamate Poisoning

The key difference lies in the nature of the enzyme-inhibitor bond:

In OP poisoning: Organophosphates bind AChE by irreversible phosphorylation. The enzyme cannot regenerate spontaneously. Oximes (pralidoxime) work by nucleophilic attack on the phosphate group, displacing it and reactivating the enzyme - this is necessary because spontaneous hydrolysis does not occur.
In carbamate poisoning: Carbamates bind AChE by reversible carbamoylation with a short half-life of approximately 30 minutes. The carbamate-AChE bond undergoes rapid, spontaneous hydrolysis and the enzyme is automatically reactivated within minutes to a few hours without needing any external agent.
Therefore, oximes are not needed in carbamate poisoning because:
1. The enzyme regenerates on its own rapidly
2. Aging does NOT occur with carbamates (unlike OPs)
3. More importantly, pralidoxime may actually potentiate toxicity of some carbamates (e.g., carbaryl), so it is actively avoided in known single-agent carbamate poisoning

Atropine alone is sufficient and usually only needed for 6-12 hours. - Tintinalli's Emergency Medicine, p.1345

Case Study 2 - Myasthenia Gravis

Q1. Reason for Symptoms

Myasthenia gravis (MG) is an autoimmune disease where the body produces antibodies against nicotinic acetylcholine receptors (nAChRs) at the neuromuscular junction (NMJ).

These antibodies cause receptor damage by three mechanisms:

Cross-linking receptors - triggers their internalization and degradation (reducing receptor number)
Complement-mediated lysis of the postsynaptic membrane
Directly blocking nicotinic receptor function

Result: The post-synaptic NMJ is severely depleted of functional ACh receptors. When a motor nerve fires, insufficient ACh signaling occurs, leading to failure of neuromuscular transmission and muscle weakness.

This explains the symptoms:

Weakness and fatigue - NMJ transmission failure, worsens with repeated use (hallmark feature)
Drooping of eyelids (ptosis) - weak levator palpebrae superioris muscle
Difficulty swallowing (dysphagia) - weakness of pharyngeal/oesophageal muscles
Reduced grip and muscle strength - generalized NMJ failure
Worsens with activity, improves with rest - classic MG pattern (depleted ACh reserves fail to trigger diminished receptors)

Confirmed by: immunoprecipitation test (anti-AChR antibodies) and EMG showing decremental response on repetitive nerve stimulation. - Katzung's Basic and Clinical Pharmacology, p.186

Q2. Drug to Relieve Symptoms with Mechanism

Pyridostigmine (first choice) or Neostigmine

Pyridostigmine:

Dose: 30-60 mg orally every 6 hours (titrated to muscle strength)
Route: Oral (for chronic management)

Mechanism: Pyridostigmine is a reversible cholinesterase (AChE) inhibitor. It binds to AChE and prevents it from breaking down acetylcholine at the NMJ. This increases the concentration of ACh in the synaptic cleft, allowing available ACh to stimulate the reduced number of nAChRs more effectively and for longer, thereby compensating for the receptor deficit and improving muscle strength.

Note: Direct-acting ACh agonists are NOT used because they would stimulate ALL cholinergic receptors non-selectively; AChE inhibitors work only where ACh is being released (at active NMJs), making them more targeted. - Katzung's Basic and Clinical Pharmacology, p.186

Q3. Other Drugs Used to Treat Myasthenia Gravis

Beyond cholinesterase inhibitors, the immunological basis of MG must be addressed:

Drug	Mechanism
Corticosteroids (prednisolone)	Immunosuppression - reduce antibody production
Azathioprine	Immunosuppressant - reduces autoantibody production (steroid-sparing)
Cyclosporine	Calcineurin inhibitor - suppresses T-cell mediated autoimmunity
Mycophenolate mofetil	Immunosuppressant
Rituximab	Anti-CD20 monoclonal antibody - depletes B cells
IVIG (IV immunoglobulins)	Modulates immune response; used in myasthenic crisis
Plasmapheresis	Removes circulating anti-AChR antibodies directly; used acutely
Thymectomy	Surgical removal of thymus (thymic hyperplasia/thymoma often drives MG); can produce lasting remission
Edrophonium	Short-acting AChE inhibitor; mainly used for diagnosis (Tensilon test), not chronic treatment

Q4. Two Drugs Contraindicated in Myasthenia Gravis

1. Aminoglycoside Antibiotics (e.g., Gentamicin, Streptomycin, Tobramycin)

Reason: Aminoglycosides block presynaptic Ca²+ channels, reducing ACh release at the NMJ. They also have a direct postsynaptic blocking effect. In MG patients, where NMJ transmission is already severely compromised, aminoglycosides can precipitate life-threatening respiratory muscle paralysis and myasthenic crisis. Patients with MG are "exquisitely sensitive" to any drugs that further interfere with neuromuscular transmission. - Katzung's Basic and Clinical Pharmacology, p.186

2. Non-depolarizing Neuromuscular Blocking Drugs (e.g., d-tubocurarine, Vecuronium, Rocuronium, Pancuronium)

Reason: These drugs compete with ACh at the nicotinic receptor - the exact same receptor already depleted in MG. MG patients have far fewer functional nAChRs, so even very small doses produce exaggerated, prolonged paralysis. The disease itself already resembles the pharmacological state produced by these drugs; adding them can cause profound and potentially fatal respiratory failure.

Other notable contraindications include:

Fluoroquinolones (e.g., ciprofloxacin) - interfere with NMJ transmission
Magnesium sulfate - reduces ACh release presynaptically
Beta-blockers - can worsen weakness
Chloroquine/hydroxychloroquine - can precipitate myasthenic crisis

Sources: Tintinalli's Emergency Medicine (9th ed.), Katzung's Basic and Clinical Pharmacology (16th ed.), Goodman & Gilman's Pharmacological Basis of Therapeutics

This is a shared conversation. Sign in to Orris to start your own chat.